A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women. - Cigler T; Richardson H; Yaffe MJ; Fabian CJ; Johnston D; Ingle JN; Nassif E; Brunner RL; Wood ME; Pater JL; Hu H; Qi S; et al. (Breast cancer research and treatment, 2011)